The Biden-Harris administration on Friday announced it is dropping—for now―a plan to ban menthol cigarettes after months of speculation about the proposal’s future. U.S. Department of Health and Human Services Secretary Xavier Becerra did not say when or if the administration would revisit the issue, nor did he mention the fate of a related proposal to ban flavored cigars.
Nearly 50% of nurses who leave the profession say they chose to do so because of burnout or insufficient staffing, according to the results of a new survey that nurse researchers reported in JAMA Network Open.
Efficient communication and care coordination are critical for high-quality patient care in ambulatory oncology settings. Electronic huddles, where the cancer team connects in a virtual space to share critical insights and make collective decisions about patient care, leverage technology to facilitate interprofessional communication and decision-making.
On April 29, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval to tisotumab vedotin-tftv (Tivdak®) for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tisotumab vedotin-tftv previously received accelerated approval for the indication.
The Cancer Equity Leaders is a diverse team of premier cancer research leaders working under the National Cancer Institute (NCI) Center to Reduce Cancer Health Disparities. NCI announced the group and its members in an April 2024 blog post.
Lifting the veil on prostate cancer and sharing lifesaving information, former National Institutes of Health (NIH) Director Francis S. Collins, MD, PhD, revealed in April 2024 that his active surveillance, slow-growing prostate cancer had advanced to a Gleason score of 9. Collins made the announcement in a Washington Post perspective piece in which he accounted his experience from both a patient and clinician lens.
Remote verification methods through virtual care nurse models and telehealth technologies have merit, but the evidence is inadequate to determine safety or efficacy, according to the latest findings from a team of ONS members and staff that were published in the Clinical Journal of Oncology Nursing.
On April 23, 2024, the U.S. Food and Drug Administration (FDA) approved lutetium Lu 177 dotatate (Lutathera®) for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors. FDA approved lutetium Lu 177 dotatate for the indication for adults in 2018.
On April 23, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tovorafenib (Ojemda™) for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement or BRAF V600 variant.
In stark contrast to a nationwide decline, cervical cancer incidence and mortality rates are increasing in low-income U.S. counties, researchers reported in the International Journal of Cancer.